Kidney Week 2011 Secondary Hyperparathyroidism

If not, please take a few moments to fill out the form below. It’s free, and ensures that you receive regular alerts to the latest clinical news and other content.

Email*

Password*

Keep me logged in Forgot your password?

Email*

Secondary Hyperparathyroidism Coverage

Calcifediol May Improve PTH Control, Nutritional Status

Jody A. Charnow November 12, 2011

PHILADELPHIA—Adequate doses of calcifediol can correct 25-hydroxyvitamin D deficiency and improve malnutrition-inflammation status in hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT), researchers reported at Kidney Week 2011.

Cinacalcet Plus Low-Dose Vitamin D Improves SHPT Treatment

Jody A. Charnow November 12, 2011

PHILADELPHIA—Cinacalcet plus low-dose vitamin D provides a more effective approach to treating secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients, according to findings presented at Kidney Week 2011.

Uncontrolled SHPT On the Rise in Blacks Since Debut of 'Bundling'

Jody A. Charnow November 12, 2011

PHILADELPHIA—Uncontrolled secondary hyperparathyroidism (SHPT) has been on the increase among black hemodialysis (HD) patients since the recent implementation of the federal government's prospective payment system for dialysis services, researchers reported at Kidney Week 2011.

Untreated SHPT Increases Mortality Risk

Jody A. Charnow November 11, 2011

PHILADELPHIA—Untreated secondary hyperparathyroidism (SHPT) is associated with increased mortality risk in hemodialysis (HD) patients, according to a report presented at Kidney Week 2011.

Treating SHPT with Cinacalcet Lowers Phosphorus

Jody A. Charnow November 11, 2011

PHILADELPHIA—Serum phosphorus levels in hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT) decrease during treatment with cinacalcet, data presented at Kidney Week 2011 show. This effect occurs regardless of baseline SHPT severity.

Two Vitamin D Analogues Show Similar Efficacy for SHPT

Jody A. Charnow November 11, 2011

PHILADELPHIA—Alfacalcidol and paricalcitol have similar efficacy in suppressing secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients researchers reported at Kidney Week 2011.

Vitamin D Regimen May Treat SHPT in Renal Transplant Patients

Jody A. Charnow November 10, 2011

PHILADELPHIA—Cholecalciferol with or without doxercalciferol may be an appropriate treatment for secondary hyperparathyroidism (SHPT) in kidney transplant recipients, according to the findings of a small study presented at Kidney Week 2011.

High PTH and FGF-23 Predict Vascular Calcification

Jody A. Charnow November 10, 2011

PHILADELPHIA—Elevated levels of serum parathyroid hormone (PTH) and fibroblast growth factor-23 (FGF-23) are associated with an increased likelihood of progression of vascular calcification (VC) in hemodialysis patients, French researchers reported at Kidney Week 2011.

Study Identifies Predictors of Cinacalcet Use After Transplantation

Jody A. Charnow November 10, 2011

PHILADELPHIA—The dose of cinacalcet dialysis patients receive prior to renal transplantation and their time on dialysis appear to be the most important factors associated with reintroduction of the drug during the first year following transplantation, Spanish researchers reported at Kidney Week 2011.